Drugs / PBL 1427
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01554293 | Jul 2012 → Jul 2013 | diabetes mellitus | Panacea Biotec Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBL 1427 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01554293 ↗ |
| Action | Inhibit | “Dipeptidyl peptidase (DPP)-IV inhibitor” NCT01554293 ↗ |
| Route | Oral | “A single oral dose of 20 mg of PBL 1427” NCT01554293 ↗ |